Baxter International Inc. (BAX) Stock Price & How to Invest

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.

The investment picture is a turnaround, not a growth story. Q1 2026 sales from continuing operations were about $2.7 billion (up roughly 3% reported, down about 1% organic), adjusted EPS beat expectations at $0.36, but GAAP results showed a small loss and adjusted operating margin compressed sharply on special charges, a Novum IQ pump shipment hold, supply constraints, and inflation. New CEO Andrew Hider, who joined in late 2025 with a lean-manufacturing reputation, is focused on stabilizing execution and improving margins while the company works to bring leverage down. The stock trades at a modest multiple relative to peers, reflecting both the balance-sheet overhang and skepticism about how quickly the turnaround delivers.

The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Elevated debt (around $8.6 billion long-term) constrains flexibility and makes the company sensitive to interest costs. Margins have been hit by special charges, injectable supply constraints, inflation, recall- and hurricane-related items, and tariff exposure. Competition from Becton Dickinson, ICU Medical, B. Braun, and Fresenius Kabi is intense across infusion and IV products. The turnaround is early and could take longer than management projects.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Baxter International Inc.'s investor relations page or your broker.

• Revenue (TTM, continuing ops): ~$10.7B
• Q1 2026 sales: ~$2.7B
• Q1 2026 adjusted EPS: ~$0.36
• Market cap: ~$11.5B
• Long-term debt: ~$8.6B
• Dividend (quarterly): ~$0.01 (cut Jan 2026)

Baxter trades at a modest valuation (price-to-sales near 1x) that reflects both its low-growth profile and the balance-sheet overhang. Full-year 2026 guidance calls for roughly flat to 1% sales growth on a GAAP basis. Reported profitability has been distorted by special charges, so adjusted metrics tell a more stable story than headline GAAP figures.

There are three common ways to get BAX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so BAX sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where BAX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

BAX is a transformation-stage medtech supplier whose story hinges on execution, margin recovery, and deleveraging rather than fast growth.

Whether BAX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BAX a buy?, and where the stock could go from here in the BAX stock forecast.

For income investors, whether BAX pays a dividend and how the payout looks is covered in does BAX pay a dividend?